NCT01342926

Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

A Phase 2, Multi-centre, Randomised, Double-masked, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 191 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety and efficacy of GSK933776 in the treatment of geographic atrophy secondary to age-related macular degeneration.

Detailed description

This is a Phase 2a proof of concept study designed to evaluate the safety and efficacy of GSK933776 for the treatment of geographic atrophy secondary to age-related macular degeneration. This is a placebo-controlled parallel-group study that is double masked.

Conditions

• Atrophy, Geographic

Interventions

Type	Name	Description
DRUG	GSK933776	GSK933776
DRUG	Placebo	Placebo

Timeline

• Start date: 2011-06-01
• Primary completion: 2016-04-01
• Completion: 2016-04-01
• First posted: 2011-04-27
• Last updated: 2017-05-05
• Results posted: 2017-05-05

Locations

41 sites across 2 countries: United States, Canada